Leflunomidum [Inn-Latin] en es it fr

Leflunomidum [Inn-Latin] Brand names, Leflunomidum [Inn-Latin] Analogs

Leflunomidum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Leflunomidum [Inn-Latin] Chemical_Formula


Leflunomidum [Inn-Latin] RX_link


Leflunomidum [Inn-Latin] fda sheet

Leflunomidum_[Inn-Latin] FDA

Leflunomidum [Inn-Latin] msds (material safety sheet)

Leflunomidum_[Inn-Latin] MSDS

Leflunomidum [Inn-Latin] Synthesis Reference

No information avaliable

Leflunomidum [Inn-Latin] Molecular Weight

270.207 g/mol

Leflunomidum [Inn-Latin] Melting Point

165-166 oC

Leflunomidum [Inn-Latin] H2O Solubility

21 mg/L (poorly soluble)

Leflunomidum [Inn-Latin] State


Leflunomidum [Inn-Latin] LogP


Leflunomidum [Inn-Latin] Dosage Forms


Leflunomidum [Inn-Latin] Indication

For the treatment of active rheumatoid arthritis (RA).

Leflunomidum [Inn-Latin] Pharmacology

Leflunomide is a pyrimidine synthesis inhibitor indicated in adults for the treatment of active rheumatoid arthritis (RA). RA is an auto-immune disease characterized by high T-cell activity. T cells have two pathways to synthesize pyrimidines: the salvage pathways and the de novo synthesis. At rest, T lymphocytes meet their metabolic requirements by the salvage pathway. Activated lymphocytes need to expand their pyrimidine pool 7- to 8-fold, while the purine pool is expanded only 2- to 3-fold. To meet the need for more pyrimidines, activated T cells use the de novo pathway for pyrimidine synthesis. Therefore, activated T cells, which are dependent on de novo pyrimidine synthesis, will be more affected by leflunomide's inhibition of dihydroorotate dehydrogenase than other cell types that use the salvage pathway of pyrimidine synthesis.

Leflunomidum [Inn-Latin] Absorption

Well absorbed, peak plasma concentrations appear 6-12 hours after dosing

Leflunomidum [Inn-Latin] side effects and Toxicity

LD50=100-250 mg/kg (acute oral toxicity)

Leflunomidum [Inn-Latin] Patient Information

No information avaliable

Leflunomidum [Inn-Latin] Organisms Affected

Humans and other mammals